

1

2

A glycan gate controls opening of the SARS-CoV-2 spike protein

3

4 Terra Sztain^{1†}, Surl-Hee Ahn^{1†}, Anthony T. Bogetti², Lorenzo Casalino¹, Jory A. Goldsmith³,

5 Ryan S. McCool³, Fiona L. Kearns¹, J. Andrew McCammon¹, Jason S. McLellan³, Lillian T.

6 Chong^{2*}, Rommie E. Amaro^{1*}

7

8 1. Department of Chemistry and Biochemistry, UC San Diego, La Jolla, CA 92093

9 2. Department of Chemistry, University of Pittsburgh, Pittsburgh, PA 15260

10 3. Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712

11 † These authors contributed equally to this work.

12 * contact authors: ramaro@ucsd.edu, ltchong@pitt.edu

13

14 Abstract

15 SARS-CoV-2 infection is controlled by the opening of the spike protein receptor binding domain

16 (RBD), which transitions from a glycan-shielded (down) to an exposed (up) state in order to bind

17 the human ACE2 receptor and infect cells. While snapshots of the up and down states have been

18 obtained by cryoEM and cryoET, details of the RBD opening transition evade experimental

19 characterization. Here, over 200 μ s of weighted ensemble (WE) simulations of the fully

20 glycosylated spike ectodomain allow us to characterize more than 300 continuous, kinetically

21 unbiased RBD opening pathways. Together with biolayer interferometry experiments, we reveal

22 a gating role for the N-glycan at position N343, which facilitates RBD opening. Residues D405,

23 R408, and D427 also participate. The atomic-level characterization of the glycosylated spike

24 activation mechanism provided herein achieves a new high-water mark for ensemble pathway
25 simulations and offers a foundation for understanding the fundamental mechanisms of SARS-
26 CoV-2 viral entry and infection.

27


28 **Introduction**

29 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus and
30 the causative agent of COVID-19, a disease that has caused significant morbidity and mortality
31 worldwide.^{1,2} The main infection machinery of the virus is the spike (S) protein, which sits on
32 the outside of the virus, is the first point of contact that the virion makes with the host cell, and is
33 a major viral antigen.³ A significant number of cryoEM structures of the spike protein have been
34 recently reported, collectively informing on structural states of the spike protein. The vast
35 majority of resolved structures fall into either ‘down’ or ‘up’ states, as defined by the position of
36 the receptor binding domain (RBD), which modulates interaction with the ACE2 receptor for cell
37 entry.^{4,5,6}

38

39 The RBDs must transition from a down to an up state for the receptor binding motif to be
40 accessible for ACE2 binding (**Figure 1**), and therefore the activation mechanism is essential for
41 cell entry. Mothes et al.⁷ used single-molecule fluorescence (Förster) resonance energy transfer
42 (smFRET) imaging to characterize spike dynamics in real-time. Their work showed that the
43 spike dynamically visits four distinct conformational states, the population of which are
44 modulated by the presence of the human ACE2 receptor and antibodies. However smFRET, as
45 well as conventional structural biology techniques, are unable to inform on the atomic-level
46 mechanisms underpinning such dynamical transitions. Recently, all-atom molecular dynamics

47 (MD) simulations of the spike protein with experimentally accurate glycosylation together with
48 corroborating experiments indicated the extensive shielding by spike glycans, as well as a
49 mechanical role for glycans at positions N165 and N234 in supporting the RBD in the open
50 conformation.⁸ Conventional MD simulations as performed in Casalino et al.⁸ also revealed
51 microsecond-timescale dynamics to better characterize the spike dynamics but were limited to
52 sampling configurations that were similar in energy to the cryoEM structures. Several enhanced
53 sampling MD simulations have been performed to study this pathway, however, these
54 simulations lacked glycosylation for the spike protein⁹ or involve the addition of an external
55 force¹⁰ or require a massive amount of sampling (millisecond timescale).¹¹



56
57 **Figure 1** (A) The SARS-CoV-2 spike head (gray) with glycans (dark blue) as simulated, with the stalk
58 domain and membrane (not simulated here, but shown in transparent for completeness). RBD shown in
59 cyan, receptor binding motif (RBM) in pink. Side view of the down (shielded, B) and open (exposed, C)
60 RBD. Top view of the closed (shielded, D) and open (exposed, E) RBM. Composite image of glycans
61 (dark blue lines) shows many overlapping snapshots of the glycans over the microsecond simulations.

62
63 In this study, we characterized the spike RBD opening pathway for the fully glycosylated SARS-
64 CoV-2 spike protein, in order to gain a detailed understanding of the activation mechanism. We

65 used the weighted ensemble (WE) path sampling strategy^{12,13} (**Figure S1**) to enable the
66 simulation of atomistic pathways for the spike opening process. As a path sampling strategy, WE
67 focuses computing power on the functional transitions between stable states rather than the stable
68 states themselves.¹⁴ This is achieved by running multiple trajectories in parallel and periodically
69 replicating trajectories that have transitioned from previously visited to newly visited regions of
70 configurational space¹⁵, thus minimizing the time spent waiting in the initial stable state for
71 “lucky” transitions over the free energy barrier. Given that these transitions are much faster than
72 the waiting times,^{16,17} the WE strategy can be orders of magnitude more efficient than
73 conventional MD simulations in generating pathways for rare events such as protein folding and
74 protein binding.^{18,19} This efficiency is even higher for slower processes, increasing *exponentially*
75 with the effective free energy barrier.²⁰ Not only are dynamics carried out without any biasing
76 force or modifications to the free energy landscape, but suitable assignment of statistical weights
77 to trajectories provides an *unbiased* characterization of the system’s time-dependent ensemble
78 properties.¹³ The WE strategy therefore generates continuous pathways with unbiased dynamics,
79 yielding the most direct, atomistic views for analyzing the mechanism of functional transitions,
80 including elucidation of transient states that are too fleeting to be captured by laboratory
81 experiments. Furthermore, while the strategy requires a progress coordinate toward the target
82 state, the definition of this target state need not be fixed in advance when applied under
83 equilibrium conditions,²¹ enabling us to refine the definition of the target open state of the spike
84 protein based on the probability distribution of protein conformations sampled by the simulation.
85
86 Our work characterizes a series of transition pathways of the spike opening and identifies key
87 residues, including a glycan at position N343, that participate in the opening mechanism. Our

88 simulation findings are corroborated by biolayer interferometry experiments, which demonstrate
89 a reduction in the ability of the spike to interact with ACE2 after mutation of these key residues.

90

91 **Results and Discussion**

92

93 **Weighted ensemble simulations of spike opening**

94 We used the WE strategy to generate continuous, atomistic pathways of the spike opening
95 process with unbiased dynamics (**Figure 2A-E, Movie S1**); these pathways were hundreds of ns
96 long, excluding the waiting times in the initial “down” state. The protein model was based on the
97 head region (residues 16 to 1140) of the glycosylated SARS-CoV-2 spike from Casalino et al.⁸
98 (**Figure 1**), which in turn was built on the cryoEM structure of the three-RBD-down spike (PDB
99 ID: 6VXX⁵). The entire simulation system, including explicit water and salt ions, reaches almost
100 half a million atoms. We focused sampling along a two-dimensional progress coordinate to track
101 RBD opening: the difference in the center of mass of the spike core to the RBD and the root
102 mean squared deviation (RMSD) of the RBD (**Figure 2F-G**). On the SDSC Comet and TACC
103 Longhorn supercomputers, 100 GPUs ran the WE simulations in parallel for over a month,
104 generating over 200 μ s of glycosylated spike trajectories and more than 200 TB of trajectory
105 data. We simulated a total of 310 independent pathways, including 204 pathways from the RBD
106 “down” conformation (PDB ID: 6VXX⁵) to the RBD “up” conformation (PDB ID: 6VSB⁴) and
107 106 pathways from the RBD “down” to RBD “open” state in which the RBD twists open beyond
108 the cryoEM structure (PDB ID: 6VSB⁴). Remarkably, the open state that we sampled includes
109 conformations that align closely with the ACE2-bound spike cryoEM structure (PDB ID: 7A95⁶)
110 even though this structure was not a target state of our progress coordinate (**Figure 2F-G, Movie**

111 **S1, Figures S2-3**). This result underscores the value of using (i) equilibrium WE simulations that
112 do not require a fixed definition of the target state and (ii) a two-dimensional progress coordinate
113 that allows the simulations to sample unexpected conformational space along multiple degrees of
114 freedom. The ACE2-bound spike conformation has also been sampled by the Folding@home
115 distributed computing project,¹¹ and RBD rotation has been detected in cryoEM experiments.⁶

116

117 **The N343 glycan gates RBD opening**

118 In the down state, the RBD of the SARS-CoV-2 spike is shielded by glycans at positions N165,
119 N234, and N343.²² Beyond shielding, a structural role for glycans at positions N165 and N234
120 has been recently reported, stabilizing the RBD in the up conformation.⁸

121


122 Our WE simulations reveal an even more specific, critical role of a glycan in the opening
123 mechanism of the spike: the N343 glycan acts as a “glycan gate” pushing up the RBD by
124 intercalating between residues F490, Y489, F456, and R457 of the ACE2 binding motif in a
125 “hand-jive” motion (**Figure 2A-E, Figure 3, Movie S2**). This gating mechanism was initially
126 visualized in several successful pathways of spike opening and then confirmed through analysis
127 of all 310 successful pathways in which the N343 glycan was found to form contacts (within 3.5
128 Å) with each of the aforementioned residues in every successful pathway (**Figure S4**). The same
129 mechanistic behavior of the N343 glycan was observed in two fully independent WE
130 simulations, suggesting the result is robust despite potentially incomplete sampling that can
131 challenge WE and other enhanced sampling simulation methods.¹⁵

132

133 To test the role of the N343 glycan as a key gating residue, we performed biolayer interferometry
134 (BLI) experiments. BLI experiments assess the binding level of the spike receptor binding motif
135 (RBM, residues 438 to 508) to ACE2, acting as a proxy for the relative proportion of RBDs in
136 the up position for each spike variant. No residues directly involved in the binding were mutated
137 (i.e., at the RBM-ACE2 interface), to ensure controlled detection of the impact of RBD opening
138 in response to mutations. Although previous results have shown reduced binding levels for
139 N165A and N234A variants in the SARS-CoV-2 S-2P protein,⁸ the N343A variant displayed an
140 even greater decrease in ACE2 binding, reducing spike binding level by ~56 % (**Figure 4, Table**
141 **S1**). As a negative control, the S383C/D985C variant,²³ which is expected to be locked by
142 disulfides into the three-RBD-down conformation, showed no association with the ACE2
143 receptor. These results support the hypothesis that the RBD up conformation is significantly
144 affected by glycosylation at position N343.


145

146



147
148
149
150
151
152
153
154
155
156
157
158


Figure 2 Atomically detailed pathways of spike opening. (A-E) Snapshot configurations along the opening pathway with chain A shown in cyan, chain B in gray, and chain C in pink and the glycan at position N343 is shown in magenta. (F) Scatter plot of data from the 310 continuous pathways with the RMSD of RBD to the 6VSB "up" state plotted against RBD — core distance. Data points are colored based on % RBD solvent accessible surface area compared to the RBD "down" state 6VXX. Location of snapshots shown in A-E are labeled. (G) Primary regions of spike defined for tracking progress of opening transition. The spike core is composed of three central helices per trimer, colored according to chain as in (A-E). The RBD contains a structured pair of antiparallel beta sheets and an overlay of snapshots from a continuous WE simulation are shown colored along a spectrum resembling the palette in (F). Overlaid cryoEM structures are highlighted and labeled including the initial RBD "down" state, 6VXX, the target RBD "up" state and the ACE2 bound "open" state, 7A95.



159
160
161
162
163

Figure 3 Glycan gating by N343. (A-D) Snapshot configurations along the opening pathway with chain A shown in cyan, chain B in gray, chain C in pink, and the glycan at position N343 is shown in magenta. (A) RBD A in the down conformation is shielded by the glycan at position N343 of the adjacent RBD B. (B-D) The N343 glycan intercalates between and underneath the residues F490, Y489, F456, F457 to push the RBD up and open (D).

164



165
166 **Figure 4** ACE2 binding is reduced by mutation of N343 glycosylation site and key salt bridge residues. (A) Bi-layer
167 interferometry sensorgrams of HexaPro spike variants binding to ACE2. For clarity, only the traces from the first
168 replicate are shown. (B) Graph of binding response for BLI data collected in triplicate with error bars representing
169 the standard deviation from the mean.
170

171 Atomic details of the opening mechanism

172 The RBD down state features a hydrogen bond between T415 of the RBD (chain A) and K986 of
173 chain C, a salt bridge between R457 of RBD_A and D364 of RBD_B, and a salt bridge between
174 K462 of RBD_A and D198 of NTD_C (**Figure 5A-C,E Figure S5**). The hydrogen bond T415_A -
175 K986_C spends an average of 12% of the successful pathways to the up state before K986_C makes
176 a short lived (2% average duration to up state) salt bridge with RBD_A D427. (**Figure 5B,E**
177 **Figure S3**) Next, K986_C forms salt bridges with E990_C and E748_C as the RBD_A continues to

178 open. These contacts are formed in all 310 successful pathways (**Figure S5**). Mutation of K986
179 to proline has been used to stabilize the pre-fusion spike,^{24,25} including in vaccine development,²⁶
180 and these simulations provide molecular context to an additional role of this residue in RBD
181 opening.


182
183 Subsequently, at an average of 16% of the way through the successful pathways to the up state,
184 the R457_A - D364_B salt bridge is broken, prompting the RBD_A to twist upward, away from RBD_B
185 towards RBD_C and forms a salt bridge between R408 of RBD_A and D405 of RBD_C (**Figure 5C**
186 **and 5E, Figure S5**). This salt bridge persists for 20% of the successful trajectories to the up
187 state, and is also present in all 310 successful pathways.

188
189 A salt bridge between R466 of RBD_A and E132 from NTD_B is present in 189 out of 204
190 successful pathways to the up state, and all 106 pathways to the open state. This contact is most
191 prevalent during the transition between the up and open state. Finally, the salt bridge between
192 D428 of RBD_A and R454 of RBD_C is present only in all 106 pathways from the up to the open
193 state and is the last salt bridge between the RBD and the spike in the open state before the S1
194 subunit begins to peel off (**Figure 5D and 5E, Figure S5**), at which point the last remaining
195 contact to the RBD_A is the glycan at position N165 of NTD_B.

196
197 Additional BLI experiments of the key identified spike residues R408A, D405A, and D427A
198 corroborate the pathways observed in our simulations. Each of these reduces the binding
199 interactions of the spike with ACE2 by ~13%, ~27%, and ~52%, respectively (**Figure 4, Table**
200 **S1**). We also note that identified residues D198, N343, D364, D405, R408, T415, D427, D428,

201 R454, R457, R466, E748, K986 and E990 are conserved between SARS-CoV and SARS-CoV-2
202 spikes, supporting their significance in coordinating the primary spike function of RBD opening.
203 The emerging mutant SARS-CoV-2 strains B.1: D614G; B.1.1.7: H69-V70 deletion, Y144-Y145
204 deletions, N501Y, A570D, D614G, P681H, T716I, S982A, D1118H; B.1.351: L18F, D80A,
205 D215G, R246I, K417N, E484K, N501Y, D614G, A701V; P1: L18F, T20N, P26S, D138Y,
206 R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and CAL.20C: L452R, D614G²⁷ do
207 not contain mutants in the residues we identified here to facilitate RBD opening. Analysis of
208 neighboring residues and glycans to those mutated in the emerging strains along the opening
209 pathway is detailed in **Table S2**, and distances between each residue and glycan to RBD_A is
210 summarized in **Movie S3**.

211



212 **Figure 5** Salt bridges and hydrogen bonds along the opening pathway. (A-D) salt bridge or hydrogen bond contacts
213 made between RBD A, shown in blue, with RBD B, shown in gray, or RBD C shown in pink within the down,
214 transient, up, and open conformations, respectively. (E) Histogram showing the frequency at which residues from
215 (A-D) are within 3.5 Å of each other relative to RBD — core distance. Frequencies are normalized to 1.
216
217
218

219

220 **Conclusions**

221 We report extensive weighted ensemble molecular dynamics simulations of the glycosylated
222 SARS-CoV-2 spike head characterizing the transition from the down to up conformation of the
223 RBD. Over 200 microseconds of simulation provide more than 300 independent RBD opening
224 transition pathways. Analysis of these pathways from independent WE simulations indicates a
225 clear gating role for the glycan at N343, which lifts and stabilizes the RBD throughout the
226 opening transition. We also characterize an “open” state of the spike RBD, in which the N165
227 glycan of chain B is the last remaining contact with the RBD *en route* to further opening of S1.
228 Biolayer interferometry experiments of residues identified as key in the opening transitions,
229 including N343, D405, R408, and D427, broadly supported our computational findings. Notably,
230 a 56% decrease in ACE2 binding of the N343A mutant, compared to a 40% decrease in N234A
231 mutant, and 10% decrease in the N165A mutant reported previously⁸ evidenced the key role of
232 N343 in gating and assisting the RBD opening process, highlighting the importance of sampling
233 functional transitions to fully understand mechanistic detail. Our work indicates a critical gating
234 role of the N343 glycan in spike opening and provides new insights to mechanisms of viral
235 infection for this important pathogen.

236

237 **Data accession**

238 We endorse the community principles around open sharing of COVID19 simulation data.²⁸ All
239 simulation input files and data are available at the NSF MolSSI COVID19 Molecular Structure
240 and Therapeutics Hub at <https://covid19.molssi.org> and the Amaro Lab website
241 <http://amarolab.ucsd.edu>.

242

243 **Author contributions**

244 T.S. and S.A. contributed equally to this work. R.E.A. and L.T.C. oversaw the project. T.S. and
245 L.C. prepared the simulation model. T.S. and S.A. performed WE simulations and A.B. provided
246 WESTPA scripts. S.A., A.B., T.S., and L.T.C. carried out WE analysis. T.S., and F.L.K.
247 performed simulation analyses. L.C., T.S., and F.L.K. created figures and movies. J.S.M.
248 designed and oversaw biolayer interferometry experiments. R.M. and J.A.G. performed biolayer
249 interferometry experiments and wrote the corresponding parts in the Results and Methods
250 sections. T.S., S.A., L.T.C., and R.E.A. wrote the manuscript with contributions from all authors.

251

252 **Funding**

253 T.S. is funded by NSF GRFP DGE-1650112. S.A. is funded by NIH grant R01-GM31749. This
254 work was supported by NIH GM132826, NSF RAPID MCB-2032054, an award from the RCSA
255 Research Corp., and a UC San Diego Moores Cancer Center 2020 SARS-COV-2 seed grant to
256 R.E.A.; NIH grant R01-GM31749 to J.A.M.; NIH grant R01-AI127521 to J.S.M; and NIH
257 (1R01GM115805-01) and NSF (CHE-1807301) to L.T.C.

258

259 **Acknowledgements**

260 We are grateful for the efforts of the Texas Advanced Computing Center (TACC)
261 Longhorn team and for the compute time made available through a Director's Discretionary
262 Allocation (made possible by the National Science Foundation award OAC-1818253). We thank
263 Dr. Zied Gaieb for helpful discussions around system construction. We thank Mahidhar Tatineni
264 for help with computing on SDSC Comet, as well as a COVID19 HPC Consortium Award for
265 compute time. We also thank Prof. Carlos Simmerling and his research group (SUNY Stony

266 Brook), and Prof. Adrian Mulholland and his research group (University of Bristol) for helpful
267 discussions related to the spike protein, as well as Prof. Daniel Zuckerman, Dr. Jeremy
268 Copperman, Dr. Matthew Zwier, and Dr. Sinam Saglam for helpful methodological discussions.

269

270 **References**

- 271 (1) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.;
272 Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.;
273 Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y.
274 A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating
275 Person-to-Person Transmission: A Study of a Family Cluster. *The Lancet* **2020**, *395*
276 (10223), 514–523. [https://doi.org/10.1016/S0140-6736\(20\)30154-9](https://doi.org/10.1016/S0140-6736(20)30154-9).
- 277 (2) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu,
278 N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.;
279 Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu,
280 W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan. W. Genomic
281 Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus
282 Origins and Receptor Binding. *Lancet* **2020**, *395* (10224), 565–574.
283 [https://doi.org/10.1016/s0140-6736\(20\)30251-8](https://doi.org/10.1016/s0140-6736(20)30251-8).
- 284 (3) Li, F. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu Rev Virol*
285 **2016**, *3* (1), 237–261. <https://doi.org/10.1146/annurev-virology-110615-042301>.
- 286 (4) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham,
287 B. S.; McLellan, J. S. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion

- 288 Conformation. *Science* **2020**, *367* (6483), 1260–1263.
- 289 <https://doi.org/10.1126/science.abb2507>.
- 290 (5) Walls, A. C.; Park, Y.-J.; Tortorici, M. A.; Wall, A.; McGuire, A. T.; Velesler, D. Structure,
291 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**, *181* (2),
292 281-292.e6. <https://doi.org/10.1016/j.cell.2020.02.058>.
- 293 (6) Benton, D. J.; Wrobel, A. G.; Xu, P.; Roustan, C.; Martin, S. R.; Rosenthal, P. B.; Skehel, J.
294 J.; Gamblin, S. J. Receptor Binding and Priming of the Spike Protein of SARS-CoV-2 for
295 Membrane Fusion. *Nature* **2020**, *588* (7837), 327–330. [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-2772-0)
296 [2772-0](https://doi.org/10.1038/s41586-020-2772-0).
- 297 (7) Lu, M.; Uchil, P. D.; Li, W.; Zheng, D.; Terry, D. S.; Gorman, J.; Shi, W.; Zhang, B.;
298 Zhou, T.; Ding, S.; Gasser, R.; Prévost, J.; Beaudoin-Bussièeres, G.; Anand, S. P.; Laumaea,
299 A.; Grover, J. R.; Liu, L.; Ho, D. D.; Mascola, J. R.; Finzi, A.; Kwong, P. D.; Blanchard, S.
300 C.; Mothes, W. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus
301 Particles. *Cell Host Microbe* **2020**, *28* (6), 880-891.e8.
302 <https://doi.org/10.1016/j.chom.2020.11.001>.
- 303 (8) Casalino, L.; Gaieb, Z.; Goldsmith, J. A.; Hjorth, C. K.; Dommer, A. C.; Harbison, A. M.;
304 Fogarty, C. A.; Barros, E. P.; Taylor, B. C.; McLellan, J. S.; Fadda, E.; Amaro, R. E.
305 Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein. *ACS Cent. Sci.*
306 **2020**. <https://doi.org/10.1021/acscentsci.0c01056>.
- 307 (9) Gur, M.; Taka, E.; Yilmaz, S. Z.; Kilinc, C.; Aktas, U.; Golcuk, M. Conformational
308 Transition of SARS-CoV-2 Spike Glycoprotein between Its Closed and Open States. *J.*
309 *Chem. Phys.* **2020**, *153* (7), 075101. <https://doi.org/10.1063/5.0011141>.

- 310 (10) Fallon, L.; Belfon, K.; Raguetto, L.; Wang, Y.; Corbo, C.; Stepanenko, D.; Cuomo, A.;
311 Guerra, J.; Budhan, S.; Varghese, S.; Rizzo, R.; Simmerling, C. Free Energy Landscapes
312 for RBD Opening in SARS-CoV-2 Spike Glycoprotein Simulations Suggest Key
313 Interactions and a Potentially Druggable Allosteric Pocket. **2020**.
314 <https://doi.org/10.26434/chemrxiv.13502646.v1>.
- 315 (11) SARS-CoV-2 Simulations Go Exascale to Capture Spike Opening and Reveal Cryptic
316 Pockets Across the Proteome | bioRxiv
317 <https://www.biorxiv.org/content/10.1101/2020.06.27.175430v3> (accessed Jan 13, 2021).
- 318 (12) Huber, G. A.; Kim, S. Weighted-Ensemble Brownian Dynamics Simulations for Protein
319 Association Reactions. *Biophys. J.* **1996**, *70* (1), 97–110. [https://doi.org/10.1016/S0006-](https://doi.org/10.1016/S0006-3495(96)79552-8)
320 [3495\(96\)79552-8](https://doi.org/10.1016/S0006-3495(96)79552-8).
- 321 (13) Zhang, B. W.; Jasnow, D.; Zuckerman, D. M. The “Weighted Ensemble” Path Sampling
322 Method Is Statistically Exact for a Broad Class of Stochastic Processes and Binning
323 Procedures. *J. Chem. Phys.* **2010**, *132* (5), 054107. <https://doi.org/10.1063/1.3306345>.
- 324 (14) Chong, L. T.; Saglam, A. S.; Zuckerman, D. M. Path-Sampling Strategies for Simulating
325 Rare Events in Biomolecular Systems. *Curr Opin Struct Biol* **2017**, *43*, 88–94.
326 <https://doi.org/10.1016/j.sbi.2016.11.019>.
- 327 (15) Zuckerman, D. M.; Chong, L. T. Weighted Ensemble Simulation: Review of Methodology,
328 Applications, and Software. *Annu Rev Biophys* **2017**, *46*, 43–57.
329 <https://doi.org/10.1146/annurev-biophys-070816-033834>.
- 330 (16) Pratt, L. R. A Statistical Method for Identifying Transition States in High Dimensional
331 Problems. *J. Chem. Phys.* **1986**, *85* (9), 5045–5048. <https://doi.org/10.1063/1.451695>.

- 332 (17) Zuckerman, D. M.; Woolf, T. B. Transition Events in Butane Simulations: Similarities
333 across Models. *J. Chem. Phys.* **2002**, *116* (6), 2586–2591.
334 <https://doi.org/10.1063/1.1433501>.
- 335 (18) Adhikari, U.; Mostofian, B.; Copperman, J.; Subramanian, S. R.; Petersen, A. A.;
336 Zuckerman, D. M. Computational Estimation of Microsecond to Second Atomistic Folding
337 Times. *J Am Chem Soc* **2019**, *141* (16), 6519–6526. <https://doi.org/10.1021/jacs.8b10735>.
- 338 (19) Saglam, A. S.; Chong, L. T. Protein–Protein Binding Pathways and Calculations of Rate
339 Constants Using Fully-Continuous, Explicit-Solvent Simulations. *Chem. Sci.* **2019**, *10* (8),
340 2360–2372. <https://doi.org/10.1039/C8SC04811H>.
- 341 (20) DeGrave, A. J.; Ha, J.-H.; Loh, S. N.; Chong, L. T. Large Enhancement of Response Times
342 of a Protein Conformational Switch by Computational Design. *Nature Communications*
343 **2018**, *9* (1), 1013. <https://doi.org/10.1038/s41467-018-03228-6>.
- 344 (21) Suárez, E.; Lettieri, S.; Zwier, M. C.; Stringer, C. A.; Subramanian, S. R.; Chong, L. T.;
345 Zuckerman, D. M. Simultaneous Computation of Dynamical and Equilibrium Information
346 Using a Weighted Ensemble of Trajectories. *J. Chem. Theory Comput.* **2014**, *10* (7), 2658–
347 2667. <https://doi.org/10.1021/ct401065r>.
- 348 (22) Watanabe, Y.; Allen, J. D.; Wrapp, D.; McLellan, J. S.; Crispin, M. Site-Specific Glycan
349 Analysis of the SARS-CoV-2 Spike. *Science* **2020**.
350 <https://doi.org/10.1126/science.abb9983>.
- 351 (23) Henderson, R.; Edwards, R. J.; Mansouri, K.; Janowska, K.; Stalls, V.; Gobeil, S. M. C.;
352 Kopp, M.; Li, D.; Parks, R.; Hsu, A. L.; Borgnia, M. J.; Haynes, B. F.; Acharya, P.
353 Controlling the SARS-CoV-2 Spike Glycoprotein Conformation. *Nature Structural &*
354 *Molecular Biology* **2020**, *27* (10), 925–933. <https://doi.org/10.1038/s41594-020-0479-4>.

- 355 (24) Pallesen, J.; Wang, N.; Corbett, K. S.; Wrapp, D.; Kirchdoerfer, R. N.; Turner, H. L.;
356 Cottrell, C. A.; Becker, M. M.; Wang, L.; Shi, W.; Kong, W.-P.; Andres, E. L.; Kettenbach,
357 A. N.; Denison, M. R.; Chappell, J. D.; Graham, B. S.; Ward, A. B.; McLellan, J. S.
358 Immunogenicity and Structures of a Rationally Designed Prefusion MERS-CoV Spike
359 Antigen. *PNAS* **2017**, *114* (35), E7348–E7357. <https://doi.org/10.1073/pnas.1707304114>.
- 360 (25) Hsieh, C.-L.; Goldsmith, J. A.; Schaub, J. M.; DiVenere, A. M.; Kuo, H.-C.; Javanmardi,
361 K.; Le, K. C.; Wrapp, D.; Lee, A. G.; Liu, Y.; Chou, C.-W.; Byrne, P. O.; Hjorth, C. K.;
362 Johnson, N. V.; Ludes-Meyers, J.; Nguyen, A. W.; Park, J.; Wang, N.; Amengor, D.;
363 Lavinder, J. J.; Ippolito, G. C.; Maynard, J. A.; Finkelstein, I. J.; McLellan, J. S. Structure-
364 Based Design of Prefusion-Stabilized SARS-CoV-2 Spikes. *Science* **2020**, *369* (6510),
365 1501–1505. <https://doi.org/10.1126/science.abd0826>.
- 366 (26) Ryan Cross. The Tiny Tweak behind COVID-19 Vaccines. *Chemical & Engineering News*.
367 September 29, 2020.
- 368 (27) Corum, J.; Zimmer, C. Coronavirus Variants and Mutations. *The New York Times*. February
369 10, 2021.
- 370 (28) Amaro, R. E.; Mulholland, A. J. A Community Letter Regarding Sharing Biomolecular
371 Simulation Data for COVID-19. *J. Chem. Inf. Model.* **2020**, *60* (6), 2653–2656.
372 <https://doi.org/10.1021/acs.jcim.0c00319>.